A Study on Pathogenic Surveillance and Nasopharyngeal Carriage of Children and Adolescents Based on Hospitals and Communities in Hainan Province

Sponsor
Huashan Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05912010
Collaborator
(none)
6,000
5
20.3
1200
59.2

Study Details

Study Description

Brief Summary

This study intends to screen children under the age of 10 for respiratory pathogens,

Streptococcus pneumoniae, and serotyping in three representative cities in Hainan province:

Haikou, Wanning, and Baisha, in order to provide a foundation for the subsequent promotion of Streptococcus pneumoniae vaccines.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: NP/OP swab

Detailed Description

The purpose of this multi-center epidemiological study was to determine the carrier status of clinically diagnosed pneumonia, pathogen spectrum of clinically diagnosed pneumonia, serotype distribution, and drug resistance profile of Streptococcus pneumoniae in sick children from hospitals and healthy children from the community.

Study Design

Study Type:
Observational
Anticipated Enrollment :
6000 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
A Study on Pathogenic Surveillance and Nasopharyngeal Carriage of Children and Adolescents Based on Hospitals and Communities in Hainan Province
Actual Study Start Date :
Apr 24, 2023
Anticipated Primary Completion Date :
Dec 31, 2024
Anticipated Study Completion Date :
Dec 31, 2024

Arms and Interventions

Arm Intervention/Treatment
case group

patients from fever clinics and pediatric wards

Diagnostic Test: NP/OP swab
NP/OP (nasopharyngeal/oropharyngeal) swabs will be collected from all cases at enrollment for respiratory pathogen multiplex PCR or pneumococcus culture.

control group

healthy community children

Diagnostic Test: NP/OP swab
NP/OP (nasopharyngeal/oropharyngeal) swabs will be collected from all cases at enrollment for respiratory pathogen multiplex PCR or pneumococcus culture.

Outcome Measures

Primary Outcome Measures

  1. Prevalence of pneumococcus [1 day]

    Estimate the prevalence of pneumococcus among children aged<10 years old hospitalized with clinical diagnosed pneumonia, in children seen at outpatient clinics, and among healthy children in the community in Hainan

  2. Correaltion index of high load (>6.9 log10 copies/ml) pneumococcus [1 day]

    Estimate the association with disease (i.e., case-control status) of high load (>6.9 log10 copies/ml) pneumococcus among outpatient or hospitalized patients with clinical diagnosed pneumonia in children aged<10 years old and among healthy children in the community in Hainan

  3. Correaltion index of disease status of infection with different pathogens [1 day]

    Estimate the association with disease status of infection with pathogens of interest (or combination of pathogens) among children aged<10 years old hospitalized with clinical diagnosed pneumonia compared to healthy children in the community in Hainan. The study is designed to be the case-control study

Secondary Outcome Measures

  1. Estimate the proportions of srotypes in patients and healthy children [1 day]

    Estimate the pneumococcal serotype distribution in children aged<10 years old with clinically diagnosed pneumonia carrying pneumococcus in Hainan.

  2. Describe the resistance proportion of antibiotics in different region in Hainan [1 day]

    Describe the antimicrobial resistance patterns in children aged<10 years old with clinically diagnosed pneumonia carrying pneumococcus in Hainan.

Eligibility Criteria

Criteria

Ages Eligible for Study:
1 Month to 10 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
    1. Case group: patients from fever clinics and pediatric wards

Patients with at least one of the following will be clinically diagnosed with pneumonia and recommended for NP/OP, blood cultures, or induced sputum as clinically indicated (TB only or if performed routinely by the clinician), bronchoalveolar lavage fluid (BALF , according to clinical requirements), pleural effusion (according to clinical requirements), and chest

X-ray examination:
  1. Shortness of breath ( children <2 months, respiratory rate ≥60 breaths/min; children ≥2 months to <12 months, respiratory rate ≥50 breaths/min; children ≥12 months to < 60 months, respiratory rate ≥40 breaths/min; Children ≥ 60 months to < 120 months, respiratory rate > 24 breaths/minute )

  2. Rales on lung auscultation

  3. Respiratory symptoms and fever ( axillary temperature ≥ 37.5 ℃ or rectal temperature ≥ 38 ℃ )

    1. Control group The control group will be randomly selected from the community and frequency-matched 1:1 with the case group according to age group, sex and city.
Exclusion Criteria:
    1. Hospitalized within the first 14 days, or discharged as a case group within the first 30 days, and lived outside the research center area ;
    1. People who affect the research results: patients cannot keep samples or the amount of samples is not enough for testing;
    1. Can't cooperate well;
    1. The researcher judges that it is not suitable to be included in this study .

Contacts and Locations

Locations

Site City State Country Postal Code
1 People's Hospital of Baisha Li Autonomous County Baisha Hainan China
2 Haikou Hospital of the Maternal and Child Health Haikou Hainan China
3 Hainan Women and Childrens Medical Center Haikou Hainan China
4 The First Affiliated Hospital of Hainan Medical University Haikou Hainan China
5 People's Hospital of Wanning Wanning Hainan China

Sponsors and Collaborators

  • Huashan Hospital

Investigators

  • Principal Investigator: Wenhong Zhang, M.D., Huashan Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Wen-hong Zhang, Director of Division of Infectious Diseases Affiliation: Huashan Hospital, Huashan Hospital
ClinicalTrials.gov Identifier:
NCT05912010
Other Study ID Numbers:
  • HAPEC-Stage one 01&02
First Posted:
Jun 22, 2023
Last Update Posted:
Jun 27, 2023
Last Verified:
Jun 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 27, 2023